Jove
Visualize
Contact Us

Related Experiment Videos

Diffuse large cell lymphoma. Prognostic factors with treatment.

D J Straus1, G Wong, J Yahalom

  • 1Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Leukemia
|January 1, 1991
PubMed
Summary

Chemotherapy protocols for diffuse large cell lymphoma (DLCL) yield similar survival rates (35-45%). Advanced age, bulky disease, and high LDH levels predict poorer outcomes, while autologous bone marrow transplant shows promise in younger patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbiome associations with acute malnutrition relapse in South Sudan.

Microbiology spectrum·2026
Same author

Implementing recommendations to optimise professional support in the medical workplace: A participatory approach.

Medical education·2025
Same author

Exploring health and social care preferences for people with dementia and mild cognitive impairment: a systematic review of discrete choice experiments.

Aging & mental health·2025
Same author

Women's engagement with community perinatal mental health services: a realist evaluation.

BMC psychiatry·2024
Same author

Assessment of an AI-based tool for population-wide collection of placental morphological data.

European journal of obstetrics, gynecology, and reproductive biology·2024
Same author

Study protocol for The GOAL Trial: comprehensive geriatric assessment for frail older people with chronic kidney disease to increase attainment of patient-identified goals-a cluster randomised controlled trial.

Trials·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Hematology
  • Clinical Medicine

Background:

  • Diffuse large cell lymphoma (DLCL) treatment has evolved with multiple chemotherapy protocols.
  • Overall survival rates for advanced stages (II-IV) have plateaued between 35% and 45% across different regimens.
  • Identifying prognostic factors is crucial for refining treatment strategies in DLCL.

Purpose of the Study:

  • To evaluate the effectiveness of successive chemotherapy protocols for DLCL stages II, III, and IV.
  • To identify prognostic factors influencing survival in DLCL patients.
  • To explore the potential of intensified treatment approaches, including autologous bone marrow transplantation (ABMT) and radiation therapy (RT), for specific patient subgroups.

Main Methods:

  • Analysis of survival data from patients undergoing five successive chemotherapy protocols for DLCL stages II-IV.

Related Experiment Videos

  • Multivariate analysis using the Weibull model to identify factors associated with survival.
  • Evaluation of outcomes in young patients with bulky disease and high lactate dehydrogenase (LDH) levels treated with high-dose chemotherapy, RT, and ABMT.
  • Review of a randomized trial comparing RT followed by adjuvant chemotherapy versus RT alone for early-stage (I/IE) diffuse lymphomas.

    • Main Results:

    • All five chemotherapy protocols demonstrated similar overall survival rates for DLCL stages II-IV.
    • Bulky mediastinal/retroperitoneal disease, elevated serum LDH, and advanced age were significantly associated with shortened survival.
    • In younger patients with bulky disease and high LDH, ABMT following high-dose chemotherapy and RT showed promising results.
    • A randomized trial indicated significantly longer disease-free survival for early-stage diffuse lymphomas treated with RT plus adjuvant chemotherapy compared to RT alone.

    Conclusions:

    • Standard chemotherapy protocols offer comparable survival outcomes for advanced DLCL.
    • Prognostic factors like bulky disease, elevated LDH, and age are critical for predicting DLCL patient outcomes.
    • Intensified treatment strategies, including ABMT, may improve survival for select DLCL patient groups.
    • Adjuvant chemotherapy following RT significantly enhances disease-free survival in early-stage diffuse lymphomas.